References
- Yildirim MS, Ozturk K, Acar H, Arbag H, Ulku CH. Chromosome 8 aneuploidy in acquired cholesteatoma. Acta Otolaryngol 2003; 123: 372–6
- Lavezzi A, Mantovani M, Cazzulo A, Turconi P, Matturri L. Significance of trisomy 7 related to PCNA index in cholesteatoma. Am J Otolaryngol 1998; 19: 109–12
- Huisman MA, De Heer E, Grote JJ. Survival signaling and terminal differentiation in cholesteatoma epithelium. Acta Otolaryngol 2007; 127: 424–9
- Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59–71
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–7
- Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29–39
- Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001; 7: 892–5
- Zhang P, Steinberg BM. Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas. Cancer Res 2000; 60: 1457–62
- Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998; 8: 1195–8
- He L, Fan C, Gillis A, Feng X, Sanatani M, Hotte S, et al. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim Biophys Acta 2007; 1772: 1134–42
- Murayama K, Kimura T, Tarutani M, Tomooka M, Hayashi R, Okabe M, et al. Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors. Oncogene 2007; 26: 4882–8
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231–41
- Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000; 60: 5390–4
- Metcalfe SM, Canman CE, Milner J, Morris RE, Goldman S, Kastan MB. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene 1997; 15: 1635–42
- Leslie NR, Downes CP. PTEN function: how normal cells control it and tumor cells lose it. Biochem J 2004; 382: 1–11
- Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005; 25: 6211–24
- Liu JL, Mao Z, LaFortune TA, Allonso MM, Gallick GE, Fueyo J, et al. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 2007; 67: 11054–63
- Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22: 183–98
- Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64: 3014–21